BRVO

Bravo Multinational, Inc. Hires Richard Jones of Jones & Haley, P.C. as a Legal Advisor to Assist with Uplisting

Retrieved on: 
Tuesday, March 12, 2024
BRVO, Disclosure, P.C, OTC

With decades of legal and financial expertise in guiding public companies, Jones holds the designation of DAD (Attorney Designated Advisor for Disclosure) for OTC Markets.

Key Points: 
  • With decades of legal and financial expertise in guiding public companies, Jones holds the designation of DAD (Attorney Designated Advisor for Disclosure) for OTC Markets.
  • Renowned in the public company deal flow arena, Jones has facilitated numerous companies in achieving their listing and uplisting objectives.
  • Grant Cramer, Chairman and CEO of Bravo Multinational, Inc. , states, "We are excited to announce this important next step in our uplisting process.
  • Rick will assist our corporate team with the expertise necessary for a successful transaction.

IBN Coverage Initiated for Bravo Multinational Inc.

Retrieved on: 
Thursday, February 22, 2024
Social media, Bravo, OTC, IBN, BRVO, Google Play, Roku, Apple, VOD

Bravo Multinational is focused on pioneering innovative solutions in the digital content landscape.

Key Points: 
  • Bravo Multinational is focused on pioneering innovative solutions in the digital content landscape.
  • As part of the Client Partner relationship, IBN will leverage its investor based distribution network of 5,000+ key syndication outlets , various newsletters , social media channels , wire services via InvestorWire , blogs and other outreach tools to generate greater awareness for Bravo Multinational .
  • IBN is uniquely positioned to provide Bravo Multinational the solutions needed to reach a wide audience of investors, journalists and the general public.
  • To learn more about Bravo Multinational, please visit the company’s corporate newsroom @ https://IBN.fm/BRVO

Bravo Multinational, Inc. Forges Ahead Into Streaming Entertainment Industry

Retrieved on: 
Friday, February 9, 2024
Video, Agreement, Addiction, BRVO, Roku, Google Play, Acquisition, Ecosystem, OTC, Platform, Smart TV, Apple Store, AVOD, H.E.R, Smartphone, SVOD, IMDb, CTV, OTT, Music

VIRGINIA BEACH, Va., Feb. 09, 2024 (GLOBE NEWSWIRE) -- Bravo Multinational, Inc. (OTC: BRVO) ($Bravo) (“Bravo” or the “Company”) announces it has entered into an Asset Purchase Agreement (the “Agreement”) to acquire the assets of Streaming TVEE, Inc., thus solidifying its entry into the dynamic world of streaming.

Key Points: 
  • VIRGINIA BEACH, Va., Feb. 09, 2024 (GLOBE NEWSWIRE) -- Bravo Multinational, Inc. (OTC: BRVO) ($Bravo) (“Bravo” or the “Company”) announces it has entered into an Asset Purchase Agreement (the “Agreement”) to acquire the assets of Streaming TVEE, Inc., thus solidifying its entry into the dynamic world of streaming.
  • “Fueling this transformative journey is a commitment to technical innovation, where state-of-the-art features and cutting-edge technology converge to create a seamless and immersive streaming experience.
  • Viewers can expect a user-friendly interface, enhanced streaming quality, and innovative features that elevate the entertainment quotient,” says Grant Cramer ( IMDb ), CEO of Bravo.
  • “This marks a pivotal moment for Bravo,” says COO of Bravo, Kayla Slick .

New Long-Term Data for Genentech’s Vabysmo Show Sustained Retinal Drying and Vision Improvements in Retinal Vein Occlusion (RVO)

Retrieved on: 
Thursday, February 1, 2024
Biotechnology, Health, Pharmaceutical, Optical, Clinical Trials, Paratriathlon, Inflammation, Ranibizumab, Research, Ophthalmology, RVO, Patient, Diabetic retinopathy, Swelling, CRVO, BRVO, Food, ROG, Bascom Palmer Eye Institute, Retina, Blood, Macular edema, Angiogenesis, Roche, Eye, CST, Telescopic sight

In addition, patients in the studies maintained vision gains and robust retinal drying achieved in the first 24 weeks of the studies for more than one year.

Key Points: 
  • In addition, patients in the studies maintained vision gains and robust retinal drying achieved in the first 24 weeks of the studies for more than one year.
  • Retinal drying is an important clinical measure as swelling from excess fluid in the back of the eye has been associated with distorted and blurred vision.
  • In both studies, Vabysmo was well tolerated and the safety profile was consistent with previous studies.
  • “The sustained vision improvements and retinal drying seen up to 72 weeks reaffirm Vabysmo as an effective treatment for retinal vein occlusion,” said Ramin Tadayoni, M.D., Ph.D., head of ophthalmology at Université Paris Cité in Paris and president of EURETINA, who is presenting the data at Angiogenesis.

Bravo Multinational, Inc. (BRVO) Announces the Signing of a Letter of Intent to Acquire Streaming TVEE Assets to Launch TVee NOW™

Retrieved on: 
Friday, January 19, 2024
LOI, OTC, STV, BRVO, Nature

VIRGINIA BEACH, Va., Jan. 19, 2024 (GLOBE NEWSWIRE) -- On December 20, 2023, Bravo Multinational, Inc. (OTC: BRVO) ($BRVO) (“Bravo”) entered a Letter of Intent (the “LOI”) to acquire certain assets of Streaming TVEE, Inc. (“STV”).

Key Points: 
  • VIRGINIA BEACH, Va., Jan. 19, 2024 (GLOBE NEWSWIRE) -- On December 20, 2023, Bravo Multinational, Inc. (OTC: BRVO) ($BRVO) (“Bravo”) entered a Letter of Intent (the “LOI”) to acquire certain assets of Streaming TVEE, Inc. (“STV”).
  • The purchase price for the assets is $9,760,000, consisting of a convertible promissory note in the amount of $7,760,000 and an assumption of $2,000,000 in STV debt.
  • The LOI is subject to normal terms of an agreement of that nature.
  • This transaction, if consummated, will serve as a business foundation for the Company’s planned development of a streaming service called TVee NOW™.

Human medicines European public assessment report (EPAR): Yesafili, aflibercept, Date of authorisation: 15/09/2023, Revision: 1, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Medical Subject Headings, Floater, Cataract, Marketing, Protein, BRVO, INN, Neovascularization, Complication, ATC, DME, Endophthalmitis, Retinal detachment, Blood, Bleeding, International, Ranibizumab, AMD, Injection, Disease, Diabetes, Language, CRVO, Eye, Pressure, Swelling, Inflammation, Intraocular pressure, RVO, European Medicines Agency, Infection, Cerebral edema, CNV, Growth, Select, Macular edema, Patient, Safety, Anatomy, Paratriathlon, Retina, IIA, Retinal haemorrhage, Three-body problem, Medical device

Human medicines European public assessment report (EPAR): Yesafili, aflibercept, Date of authorisation: 15/09/2023, Revision: 1, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Yesafili, aflibercept, Date of authorisation: 15/09/2023, Revision: 1, Status: Authorised

Genentech’s Vabysmo Maintained Vision Improvements With Extended Treatment Intervals Up to Four Months for People With Retinal Vein Occlusion (RVO) in Phase III Trials

Retrieved on: 
Tuesday, October 10, 2023
Research, FDA, Clinical Trials, Biotechnology, Managed Care, Health, Pharmaceutical, Optical, Science, Retina, Paratriathlon, European, HIV disease progression rates, RVO, Angiogenesis, Food, Neovascularization, Inflammation, DME, United Kingdom, Roche, ROG, CRVO, BRVO, AMD, Blood, Phase, RO, Faricimab, Diabetic retinopathy, Maintenance, Macular edema, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, European Medicines Agency, Pharmaceutical industry, Medical imaging, Vaccine, Genentech

Data showed people treated with Vabysmo extended their treatment intervals up to every four months while maintaining the vision gains achieved in the first 24 weeks of the trials.

Key Points: 
  • Data showed people treated with Vabysmo extended their treatment intervals up to every four months while maintaining the vision gains achieved in the first 24 weeks of the trials.
  • Vabysmo continued to show robust and sustained drying of retinal fluid from baseline up to week 72, as measured by reduction in central subfield thickness.
  • This is the first time that vision and anatomical improvements have been maintained for more than a year using a personalized treat-and-extend dosing regimen in both global Phase III BRVO and CRVO trials.
  • In both studies, Vabysmo was generally well-tolerated and the safety profile was consistent with previous trials.

Bravo Multinational Announces Future Plans and Priorities

Retrieved on: 
Friday, September 1, 2023
Television, Advertising, Channel, Food, FAST, Internet, Bravo (American TV network), Android, AVOD, IOS, Tablet, Free, OTC, BRVO, Video game

Grant Cramer , CEO, stated, “The future launch of TVee NOW holds immense significance within our business framework.

Key Points: 
  • Grant Cramer , CEO, stated, “The future launch of TVee NOW holds immense significance within our business framework.
  • If this model is completed, it will allow Bravo to bridge the gap until the Company can ultimately create its originally produced content.
  • The plans discussed above may change and there is no assurance that they will be realized.
  • To learn more about Bravo Multinational, please visit: https://bravomultinationalinc.com .

Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2023 and Reiterates Key Anticipated Near-Term Milestones

Retrieved on: 
Monday, August 14, 2023
Retina, Injection, Bevacizumab, Partnership, PIER, Anti-VEGF, PHSA, GlobalData, Special Protection Area, DME, Pharmacy, Marketing, AMD, AmerisourceBergen, Safety, Calendar, Clinical trial, Advanced Therapy Medicinal Product, Diabetic retinopathy, Intraocular pressure, Acquisition, Alliance Healthcare, Standard of care, Patient, Physician, Fujifilm Diosynth Biotechnologies, PDUFA, MAA, FDA, CHMP, Therapy, BLA, BRVO, JAMA, Syringe, Pharmaceutical industry, Medical device, EU

By meeting strict FDA requirements for an ophthalmic approved formulation of bevacizumab, we believe we can enhance the standard of care.

Key Points: 
  • By meeting strict FDA requirements for an ophthalmic approved formulation of bevacizumab, we believe we can enhance the standard of care.
  • This represents approximately 3.5 million injections of off-label, repackaged bevacizumab each year in the United States alone.
  • Globally, the nine major markets account for an estimated $13.1 billion market for anti-VEGF drugs to treat retina diseases.
  • In August 2022, Outlook Therapeutics submitted a PHSA 351(a) BLA for ONS-5010 as an original biologic application.

Bravo Multinational (OTC: BRVO) Unveils Visionary Rebranding as an Entertainment, Technology, and Hospitality Powerhouse

Retrieved on: 
Thursday, June 22, 2023
Internet of things, Consumer, OTT, Multimedia, Attention, IP, Food, Creativity, Tablet, Recreation, Bravo, Acquisition, Collection, Television, OTC, Virtual reality, Growth, AI, BRVO, Video game, Management

The ultimate objective is to establish a highly appealing and versatile framework that provides captivating in-person and digital entertainment experiences.

Key Points: 
  • The ultimate objective is to establish a highly appealing and versatile framework that provides captivating in-person and digital entertainment experiences.
  • By intertwining the realms of technology, hospitality, arts, entertainment, and recreation, Bravo plans to adopt a cross-pollination business model.
  • The Company’s rebranding also includes a unique customer acquisition strategy which is aimed to set Bravo Multinational apart, as it harnesses revenue-sharing programs with partnered content creators, influencers, and philanthropic organizations.
  • For more information about Bravo Multinational, Inc. and to join the Company’s mailing list, please visit www.bravomultinationalinc.com .